MF3d / E+
COVID-19 Booster Shot Targeting Omicron Gets FDA Approval
On August 31, the United States Food and Drug Administration (FDA) adjusted the Emergency Use Authorization for the Pfizer and Moderna COVID-19 vaccines to include a modified dose designed to provide protection against the Omicron BA.5 variant. This is the first revision to the vaccines since they debuted in December 2020. The US has more than 170 million doses of the booster shot, which will be available to those ages 12 and older. The US Centers for Disease Control and Prevention still needs to sign off on the shots, which should be available immediately following Labor Day weekend. Click here to read more.